Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046826 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
A Phase 2 study, sponsored by Nuvance Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00046826 is a Phase 2 study that has completed, run by Nuvance Health.
The verdict
NCT00046826, a Phase 2 study, has completed, sponsored by Nuvance Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and estramustine with thalidomide in treating patients who have prostate cancer previously treated with hormone therapy.
Interventions
- DRUG docetaxel
- DRUG thalidomide
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046826
The ClinicalTrials.gov registry entry for NCT00046826 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Nuvance Health, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which docetaxel is the first listed.
NCT00046826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046826 about?
NCT00046826 is a clinical study titled "Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy". RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase II trial ...
What is the current status of trial NCT00046826?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00046826?
The interventions under investigation include: docetaxel (DRUG), thalidomide (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00046826?
This trial is sponsored by Nuvance Health, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.